I found a recent article disturbing. A large drugmaker estimates that three diabetes drugs in the pipeline have the potential to bring in sales of $3 billion in the next few years.

I could have looked at the upside of this. These are drugs that could improve the quality of life and health of many people living with diabetes.

I could have.

But what I see in this article is a positive report on the financials of a company getting a little richer every time another person gets diagnosed. News that panders to its shareholders and seems just a bit too pleased about having so many people with diabetes to treat. I see my son as a client in the business of diabetes. He's their demographic; he's the customer.

"You're talking peak sales in the multiple billions for all three drugs, if they succeed," an analyst from Miller Tabak & Co. said. (READ MORE)